Skip to main content
EBS logo

EBS · Emergent BioSolutions Inc.

Track EBS — free
$5.50 -0.11 (-1.96%) At close · Nov 18
Market Cap
$282.78M
Shares
51.42M
Volume · Nov 18 817.07K Avg daily vol (3M) 1.13M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$5.50 Open$5.60 Day$5.42–5.81 52W close$4.45–13.90 Avg vol 30d1.0M Short int10.1M · 19.6% of shares · 10.1d Short vol55% Last earningsNov 2, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 3

Up next

Feb 25, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 4
Current report 8-K
$22.3 Million BioThrax Order Modification for U.S. Department of War

Emergent BioSolutions received a modification worth up to $22.3 million to supply BioThrax® to the U.S. Department of War. The first delivery, valued at approximately $7.4 million, will begin this year, with remaining deliveries expected in 2027.

Other events
Source passage
Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has received a modification exercising an option period under its existing delivery order valued at up to $22.3 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War (DoW). The first delivery, which is valued at approximately $7.4 million, will begin this year, and remaining deliveries are expected in 2027. Open the document at this passage
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue falls 52% amid $191.3 million NARCAN impairment

Emergent BioSolutions reported that, for the three months ended September 30, 2026, revenue fell 52% to $110.0 million and gross margin fell 87% to $15.0 million, alongside a $191.3 million non-cash NARCAN impairment.

Revenue $110M ▼ 52.4% Net loss $32.7M Diluted EPS -$0.64
Read from the MD&A section
4 source passages
Emergent BioSolutions Inc. (“Emergent,” the “Company,” “we,” “us,” and “our”) is a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats (“PHTs”). Total revenues decreased $121.1 million, or 52%, to $110.0 million for the three months ended September 30, 2026. Gross margin decreased $104.8 million, or 87%, to $15.0 million for the three months ended September 30, 2026. The Company recognized a non-cash impairment charge of $191.3 million during the second quarter of 2026, which was attributed entirely to the NARCAN® finite-lived intangible asset. Open the document at this passage
Nov 2
Earnings call
Sets 2026 revenue outlook at $600 million to $645 million

Emergent BioSolutions updated full-year 2026 revenue guidance to $600 million to $645 million and adjusted EBITDA to $110 million to $140 million. Third-quarter revenue was $110 million, and CFO Rich Lindahl retires effective December 31, 2026.

5 source passages
We now expect total revenues of $600 million to $645 million, reflecting our current outlook for both the NCM and commercial segments. Finally, we now expect adjusted EBITDA of $110 million to $140 million, with the upper end of the range consistent with the midpoint of our prior guidance. our third quarter results were consistent with expectations with $110 million in revenue within our guidance range. I'm joined today by Rich Lindahl, our Chief Financial Officer. Rich has decided to retire effective December 31st, 2026. Open the document at this passage
Nov 2
Current report 8-K
Third-quarter revenue falls 52% to $110.0 million, net loss widens

Emergent BioSolutions reported third-quarter 2026 total revenues of $110.0 million, down 52%, with a net loss of $32.7 million. The company also revised its full-year 2026 revenue forecast to $600 - $645 million from $645 - $675 million.

Financial results, Regulation FD disclosure Read from the first part of this long document
4 source passages
Third Quarter 2026 Total Revenues of $110.0 million Third Quarter 2026 Net Loss of $32.7 million and Net Loss Margin was (30)% Total Revenues | 110.0 | 231.1 | (52)% Total revenues | $600 - $645 | REVISED | $645 - $675 | Open the document at this passage
Oct 16
Current report 8-K
Director or officer change, or executive pay

Emergent BioSolutions announced Richard Lindahl will retire as CFO effective December 31, 2026, transitioning to an advisor until March 31, 2027. Frank Vargo, currently VP, Treasurer, will serve as Interim CFO beginning January 1, 2027.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$649.10M
Trailing 12 months
Net income (TTM)
−$260.70M
Trailing 12 months
Revenue growth YoY
-52.4%
Year over year
Operating margin
-27.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
66.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$338.60M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-9.2%
Year over year · fewer shares
Price change (1Y)
-45.7%
Trailing year
Short interest
19.6%
Latest settlement · 10.1 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 2, 2026
Q3 FY26

TL;DR. Emergent raised full-year adjusted gross margin guidance, generated $122.4 million of year-to-date operating cash flow, reduced debt and expects restructuring to produce approximately $40 million of annualized savings. However, full-year revenue and adjusted EBITDA guidance ranges were revised lower, Q3 revenue declined 52% year over year, and Q3 adjusted EBITDA was a loss of $4.6 million.

Bullish
  • + Full-year adjusted gross margin guidance was raised to 45%-47% from 42%-44%. new
  • + Year-to-date operating cash flow increased to $122.4 million from $92.9 million in the prior-year period. new
  • + The Government of Canada awarded NARCAN a standing offer that creates a multiyear pathway. new
  • + Debt fell to $514 million of gross debt from $693 million a year earlier following a $75 million bond-principal repurchase. new
  • + Restructuring actions are expected to generate approximately $40 million of annualized savings. new
Bearish
  • − Q3 adjusted gross margin fell to 28% from 62%, with profitability affected by revenue timing, product mix and commercial-segment competition. new
  • − Q3 naloxone revenue declined 42% because of unfavorable U.S. pricing and volume mix, partly offset by Canadian growth. new
  • − Commercial revenue is expected to decline 20%-25% in 2026, with performance tracking toward the lower end of that range. new

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −28%
below
Price vs 50-day avg −15%
below
RSI (14) 34
neutral
MACD trend Negative
52-week position 11%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −11%
trailing
6-month return −40%
trailing
YTD return −56%
this year
Relative strength −36%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $6 › 200d $8 — 200d above 50d
Institutional flow Distributing
-4% holders QoQ · +32 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
19.61% of shares out · ▲ +4.1% MoM · 10.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
189 holders — mid 3-yr range
Squeeze score 78
high risk · 0–100
Fundamentals
Strong
Revenue growth −29%
Y/Y
Gross margin 43%
expanding
EPS growth +126%
Y/Y
Free cash flow $156.8M
Buyback $37.3M
remaining
Balance sheet $384.3M
net debt
Quant / Vol
risk profile
Very High
Volatility 69%
annualized · 1-yr
Max drawdown −68%
past year
ATR 6.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Beat or met 6 of last 8
Latest guidance · from the 8-K filed Nov 2, 2026
full year 2026
Adjusted EBITDA Lowered $110M – $140M
Aug 5, 2026 $130M – $150M changed to Nov 2, 2026 $110M – $140M
Adjusted gross margin % Raised 45% – 47%
Aug 5, 2026 42% – 44% changed to Nov 2, 2026 45% – 47%
R&D Lowered 6%
Apr 30, 2026 6% – 7% changed to Nov 2, 2026 6%
SG&A Raised 28% – 30%
Apr 30, 2026 26% – 28% changed to Nov 2, 2026 28% – 30%
2026 Full Year Forecast
Net loss Lowered $-255M – $-225M
Aug 5, 2026 $-245M – $-225M changed to Nov 2, 2026 $-255M – $-225M
Adjusted net income (loss) $-10M – $20M
Total revenues Lowered $600M – $645M
Aug 5, 2026 $645M – $675M changed to Nov 2, 2026 $600M – $645M
prior FY $742.9M midpoint −16.2% Y/Y
Cost of product and services sales, net $328M – $339M
Gross margin % Raised 34% – 36%
Aug 5, 2026 32% – 35% changed to Nov 2, 2026 34% – 36%
Gross margin Lowered $195M – $226M
Aug 5, 2026 $200M – $226M changed to Nov 2, 2026 $195M – $226M
Severance and restructuring costs $11M
Stock-based compensation expense $19M
Non-cash amortization charges $62M
Impairments $191M
Loss on assets held-for-sale $11M
Contingent consideration milestones $-5M
Loss on debt extinguishment $14M
Changes in fair value of financial instruments $-13M
Tax effect $-50M
Depreciation & amortization $81M
Income taxes $13M
Total interest expense, net $38M
Product and services sales, net Lowered $578M – $620M
Aug 5, 2026 $620M – $650M changed to Nov 2, 2026 $578M – $620M
Previous outlook earlier release · from the 8-K filed Aug 5, 2026

Still-open targets the latest release did not restate under the same label.

Charges in connection with the Restructuring Plan · expected to incur primarily in the second half of 2026 $10M – $11.5M
Annualized savings · when fully implemented $40M
Adjusted net income (2) · full year 2026 $10M – $30M
Adjusted gross margin · 2026 Full Year Forecast $263M – $289M
Commercial revenues · FY 2026 as of August 5, 2026 20% – 25%
R&D · Updated Range (as of 08/05/2026) 6%
SG&A · Updated Range (as of 08/05/2026) 27% – 28%
Prior guidance period ended · from the 8-K filed Aug 5, 2026
Total revenues · Q3 2026 Forecast $110M – $130M
Guided vs delivered · last 8 settled
Total revenues Q3 2026 Forecast
guided $110M – $130M
$110M In line
Total revenues Q2 2026
guided $170M – $185M
$234.3M Beat +32.0%
Total revenues Q1 2026
guided $135M – $155M
$156.1M Beat +7.7%
Total revenues 2025 Full Year Forecast
guided $775M – $835M
$742.9M Miss −7.7%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−28% Bearish
Price vs 50-day avg
−15% Bearish
RSI (14)
34 Neutral
MACD trend
Negative Bearish
52-week position
11% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $6 › 200d $8 — 200d above 50d
Institutional flow Distributing
-4% holders QoQ · +32 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
19.61% of shares out · ▲ +4.1% MoM · 10.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
189 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $4 Now $6 · 11% Range high $14
vs 200-day avg -28% vs 50-day avg -15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
average price paid 8.44 the three months ended September 30, 2026 filing —
Average price paid per share (1) $8.44 three months ended September 30, 2026 filing —
cash $68.1M the three months ended September 30, 2026 filing —
Segment adjusted gross margin %(2) non-GAAP 32% three months ended September 30, 2026 filing —
Segment adjusted gross margin reportable segments: Commercial Products non-GAAP $14 three months ended September 30, 2026 filing —
Severance Payments $8.2 the three months ended September 30, 2026 filing —
shares 0M the three months ended September 30, 2026 filing —
Total restructuring costs 9.3M the three months ended September 30, 2026 filing —
Total stock-based compensation expense $4.2 three months ended September 30, 2026 filing —
Adjusted gross margin % non-GAAP 49% YTD 2026 —
Cash utilized to repurchase Bonds $68M Q3 2026 —
Contract modification $24M Q3 2026 —
Countries supplied 13 YTD 2026 —
Cumulative Operating Cash Flow $352M through Q3 2026 —
Gross Debt $514M Q3 2026 —
Intangible asset amortization non-GAAP 7.8M Quarter Ended September 30, 2026 —
Inventory step-up provision non-GAAP 2.4M Nine Months Ended September 30, 2026 —
Net debt reduction $418M through Q3 2026 —
Net Leverage Ratio non-GAAP 2.4 As of September 30, 2026 —
New term loan 150M April 2026 —
Operating cash flow $122M YTD 2026 —
Sales closed 19 Q3 2026 —
Severance and restructuring costs (benefits) non-GAAP 1.3M Nine Months Ended September 30, 2026 —
Stock-based compensation expense non-GAAP 0.7M Quarter Ended September 30, 2026 —
Unsecured Bond Principal repurchased $75M Q3 2026 —
MCM Product gross margin percentage 64% the three months ended June 30, 2026 filing —
MCM Product segment adjusted gross margin intangible asset amortization exclusion non-GAAP $7.8M the three months ended June 30, 2026 filing —
MCM Products gross margin $107.4M the three months ended June 30, 2026 filing —
Adjusted EBITDA (Trailing twelve months) non-GAAP $241M Twelve months ended June 30, 2026 —
Remaining share repurchase authorization $46.5M Q1 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
EBS
Emergent BioSolutions Inc.
this stock
$282.78M -55.5% -28.8% — 19.6%
TAK
Takeda Pharmaceutical Co Ltd
$67.96B +36.4% — — 0.1%
GALDY
Galderma Group AG
$51.90B +7.4% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$49.28B +35.3% +4.3% 96.0 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
$40.66B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
189
% held
89.1%
Net QoQ
+1.2M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
206
View
Short & Settlement
Short Interest Rising
Shares short
10.1M
Days to cover
10.1d
Change
+395.7K sh
View
Short Volume
Short vol %
55%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
544
Value
$3.9K
As of
Oct 29, 2026
View
Off-Exchange
Off-exchange %
38.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Steve Cohen
Amount
$1.0K–$15.0K
Traded
Dec 11, 2024
View
Financials
Financials
Revenue (FY)
$742.9M
Net income (FY)
$52.6M
EPS diluted
$0.93
View
Buybacks
Authorized
$50.0M
Remaining
$37.3M
Spent Remaining
View
Filings
SEC Filings
Latest
8-K
Filed
Nov 4, 2026
This year
28

Emergent BioSolutions received a modification worth up to $22.3 million to supply BioThrax® to the U.S. Department of War. The first delivery, valued at approximately $7.4 million, will begin this year, with remaining deliveries expected in 2027.

View
Proposed Sales
Value
$126.1K
Shares
17.8K
Filed
Oct 7, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 18, 2026
View
Investor Relations
Latest news
Asimov and Emergent Biosolutions…
Published
Nov 16, 2026
View

Performance

5D 20D 120D MTD YTD
EBS -8.9% -11.3% -39.7% -19.2% -55.5%
SPY -3.9% -5.6% -3.5% -3.4% +7.1%
vs SPY -5.0% -5.7% -36.2% -15.9% -62.6%

Capital returns

Buyback program · as of Sep 30, 2026
Authorized
$50.00M
Spent (derived)
$12.70M
Remaining
$37.30M
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1367644 CUSIP 29089Q105 13F (30d) 196 filings 175 filers Visit website Investor relations